NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Recent movement.

1. Combination patent application in Europe to be granted, includes both DCVax-l (lysate pulsed) and/or DCVax-Direct (partial maturation) with checkpoint inhibitors.
2. Wednesday will mark 70 days since MAA was filed.
3. MHRA and FDA looking at further cooperation.
4. Nature Journal article on DC/poly-iclc combination study nearing publication. Primary completion date for study occurred nearly thirty days ago.
5. Active negotiations with other parties for combination trials going on for over a year, awaiting MAA to be “cemented.”
6. Large pharma struggling to adapt to upcoming patent cliffs.
7. Cohen/Milstein/Posner about to file second amended complaint, and with it, formulaic method to arrive at loss causation.
8. Flaskworks (aka: NWBO) continues IP momentum.
9. Advent hiring head of production to hire team to facilitate biotherapeutic production for clinical use. (Direct?)
10. FDA pursuing Promising Pathways.